breast cancer management
Recently Published Documents


TOTAL DOCUMENTS

425
(FIVE YEARS 129)

H-INDEX

31
(FIVE YEARS 4)

2022 ◽  
pp. 105-114
Author(s):  
Joseph Thomas ◽  
Amulya Cherukumudi ◽  
Pramod V

Cancers ◽  
2021 ◽  
Vol 13 (24) ◽  
pp. 6358
Author(s):  
Arnaud Beddok ◽  
Paul Cottu ◽  
Alain Fourquet ◽  
Youlia Kirova

Background: The objective of the present study was to review the essential knowledge about the combinations of the most commonly used or under development targeted treatments and radiation therapy (RT). Methods: Preclinical and clinical studies investigating this combination were extensively reviewed. Results: Several studies showed that the combination of RT and tamoxifen increased the risk of radiation-induced pulmonary toxicity; therefore, both modalities should not be given concomitantly. The combination of HER2 inhibitors (trastuzumab, pertuzumab) and RT seems to be safe. However, trastuzumab emtansine (T-DM1) should not be administered concurrently with brain RT since this combination could increase the risk of brain radionecrosis. The combination of RT and other new target treatments such as selective estrogen receptor degradants, lapatinib, cell cycle inhibitors, immune checkpoint inhibitors, or molecules acting on DNA damage repair seems feasible but was essentially evaluated on retrospective or prospective studies with a small number of patients. Furthermore, there is considerable heterogeneity among these studies regarding the dose and fractionation of radiation, the dosage of drugs, and the sequence of treatments used. Conclusions: The combination of RT with most targeted therapies for BC appears to be well-tolerated, but these results need to be confirmed in prospective randomized studies.


Author(s):  
Yudai Kaneda ◽  
Akihiko Ozaki ◽  
Masahiro Wada ◽  
Tomohiro Kurokawa ◽  
Toyoaki Sawano ◽  
...  

Little is known on how disasters interact in their impacts on patient care. We experienced a breast cancer patient whose initial presentation was delayed for two years due to the COVID-19 pandemic and Typhoon Hagibis. Increasing awareness is needed on the combined impacts of disasters on breast cancer management.


2021 ◽  
Vol 3 (3) ◽  
pp. 1-4
Author(s):  
Margaret Schermerhorn ◽  

Disparities exist in both breast cancer outcomes and treatment delays. Breast cancer treatment delays are multifactorial and lead to decreased survival rates and lower quality of life.


2021 ◽  
Author(s):  
Shaun Treweek ◽  
Viviane Miyakoda ◽  
Dylan Burke ◽  
Frances Shiely

Abstract Background: Randomised trials support improved decision-making through the data they collect. One important piece of data is the primary outcome – so called because it is what the investigators decide is the most important. Secondary outcomes provide additional information to support decision-making. We were interested in knowing how important patients and healthcare professionals consider the outcomes (especially the primary outcome) measured in a selection of published trials. Methods: The work had three stages: 1. We identified a body of late-stage trials in two clinical areas, breast cancer management and nephrology. 2. We identified the primary and secondary outcomes for these trials. 3. We randomly ordered these outcomes and presented them to patients and healthcare professionals (with experience of the clinical area), and we asked them to rank the importance of the outcomes. They were not told which outcomes trial authors considered primary and secondary. Results: In our sample of 44 trials with 46 primary outcomes, 29 patients, one patient representative and 12 healthcare professionals together ranked the primary outcome as the most important outcome 13/46 times, or 30%. Breast cancer patients and health care professionals considered the primary outcome to be the most important outcome for 8/21 primary outcomes chosen by trialists. For nephrology, the equivalent figure was 5/25. The primary outcome appeared in a respondent’s top 5 ranked outcomes 151/178 (85%) times for breast cancer and 225/259 (87%) times for nephrology even if the primary wasn’t considered the most important outcome. Conclusions: The primary outcome in a trial is the most important piece of data collected. It is used to determine how many participants are required, and it is the main piece of information used to judge whether the intervention is effective or not. Our study found that in the view of patients and healthcare professionals, teams doing trials in breast cancer management and nephrology got their choice of primary outcome wrong 70% of the time.


Nanomedicine ◽  
2021 ◽  
Author(s):  
Priya Gupta ◽  
Yub Raj Neupane ◽  
Suhel Parvez ◽  
Kanchan Kohli

Breast cancer is the most commonly occurring tumor disease worldwide. Breast cancer is currently managed by conventional chemotherapy, which is inadequate in curbing this heterogeneous disease and results in off-site toxic effects, suggesting effective treatment approaches with better therapeutic profiles are needed. This review, therefore, focuses on the recent advancements in delivering therapeutics to the target site using passive and/or active targeted nanodrug-delivery systems to ameliorate endolysosomal escape. In addition, recent strategies in targeting breast cancer stem cells are discussed. The role of naturally cell-secreted nanovesicles (exosomes) in the management of triple-negative breast cancer is also discussed.


2021 ◽  
Vol 268 ◽  
pp. 445-451
Author(s):  
Audrey Blazek ◽  
Cristina O'Donoghue ◽  
Samantha Terranella ◽  
Ethan Ritz ◽  
Rosalinda Alvarado ◽  
...  

2021 ◽  
Author(s):  
Gregory Veillette ◽  
Maria Castaldi ◽  
Sacha Roberts ◽  
Afshin Parsikia ◽  
Ankur Choubey ◽  
...  

Abstract Purpose The incidence of breast cancer (BC) in solid organ transplant recipients is comparable to the age-matched general population. The rate of reported de novo breast cancer following liver transplantation (LT) varies. Further, there is limited information on the management and outcomes of breast cancer in liver transplant recipients (LTR). We aim to evaluate the impact of LT on breast cancer surgery outcomes. Further we compare the outcomes after breast cancer surgery in LTR in transplant versus non-transplant centers. Methods National Inpatient Sample (NIS) database was accessed to identify LTR with BC. Mortality, complications, hospital charges and total length of stay (LOS) were evaluated with multivariate logistic regression testing. Weighted multivariate regression models were employed to compare outcomes at transplant and non-transplant centers. Results Ninety-nine women met inclusion criteria for LT + BC and were compared against a cohort of women with BC without LT (n=736,527). LT + BC had lower performance status as confirmed via higher Elixhauser Comorbidity Index (20.5% vs.10.2%, p < 0001). There were significantly more complications in the LT cohort when compared to the non-LTR (15.0% vs. 8.2%, p=0.012). However, on multivariate analysis, LT was not an independent risk factor for post-operative complications following breast cancer surgery (OR 1.223, p=0.480). Cost associated with breast cancer care was significantly higher in those with LT (2.621, p<0.001). Breast conservation surgery in LT had shorter LOS as compared to BC alone (OR 0.568, p 0.027) in all hospitals. Conclusion LT does not increase short-term mortality when undergoing breast cancer surgery. Although there were significantly more complications in the LT cohort when compared to the non-LTR (15.0% vs. 8.2%, p=0.012), on multivariate analysis, LT was not an independent risk factor for postoperative complications following breast cancer surgery. Additionally, breast cancer treatment is more costly in LTR. Breast cancer management in LTR at non-transplant centers incurred higher charges but no difference in complication rate, nor LOS when compared to breast cancer management in LTR at transplant centers.


2021 ◽  
Vol 28 (6) ◽  
pp. 4504-4520
Author(s):  
Ramon Handerson Gomes Teles ◽  
Rafael Sussumu Yano ◽  
Nicolas Jones Villarinho ◽  
Ana Sayuri Yamagata ◽  
Ruy Gastaldoni Jaeger ◽  
...  

Extracellular vesicles transport variable content and have crucial functions in cell–cell communication. The role of extracellular vesicles in cancer is a current hot topic, and no bibliometric study has ever analyzed research production regarding their role in breast cancer and indicated the trends in the field. In this way, we aimed to investigate the trends in breast cancer management involved with extracellular vesicle research. Articles were retrieved from Scopus, including all the documents published concerning breast cancer and extracellular vesicles. We analyzed authors, journals, citations, affiliations, and keywords, besides other bibliometric analyses, using R Studio version 3.6.2. and VOSviewer version 1.6.0. A total of 1151 articles were retrieved, and as the main result, our analysis revealed trending topics on biomarkers of liquid biopsy, drug delivery, chemotherapy, autophagy, and microRNA. Additionally, research related to extracellular vesicles in breast cancer has been focused on diagnosis, treatment, and mechanisms of action of breast tumor-derived vesicles. Future studies are expected to explore the role of extracellular vesicles on autophagy and microRNA, besides investigating the application of extracellular vesicles from liquid biopsies for biomarkers and drug delivery, enabling the development and validation of therapeutic strategies for specific cancers.


Sign in / Sign up

Export Citation Format

Share Document